The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News The Peptide Split: How GLP 1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewriting Medicine While BPC 157, TB 500, MOTS c, and the Wellness Grift Borrow Their Halo